Urinary void function.
Conditions
Interventions
Trade Name: Trobalt
Product Name: ezogabine/retigabine
Product Code: GW582892
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Retigabine
CAS Number: 150812-12-7
Current Sponsor code: GW58
Sponsors
GlaxoSmithKline R & D Ltd., 980 Great West Road, Brendford, Middlesex, TW8 9GS, UK
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Subjects eligible for enrolment in the study must meet all of the following criteria: 1. Is =18 years of age (male or female). 2. Has a confident diagnosis of epilepsy with partial onset seizures with or without secondary generalization (classified according to International League Against Epilepsy (ILAE) Guidelines, 1981) =2 years 3. Is currently being treated with a stable regimen of one to three AEDs during the 4 weeks prior to the Screening Visit. 4. Following Amendment 03: must be considered drug resistant, consistent with the definition proposed by Kwan, et al 2010 [Kwan] Note: Vagus Nerve Stimulator (VNS) VNS will not be counted as a concurrent AED. Subjects with surgically implanted VNS will be allowed to enter the study provided that all of the following conditions are met: • The VNS has been in place for at least 24 weeks prior to the Screening Visit • The settings must remain the same for at least 4 weeks prior to the Screening Visit and throughout the study • The battery is expected to last for the duration of the study • Subject who are considering implantation of a VNS are excluded from participating in this study Note: The chronic use of benzodiazepines as a concurrent AED is permitted as long as the dose is kept constant for at least 4 weeks before the Screen Visit and throughout the study. 5. Is able and willing to maintain an accurate and complete two (2) day Voiding Diary at protocol specified time points. 6. Is able and willing to maintain an accurate and complete daily written Seizure Calendar at specified time points or has a caregiver who is able and willing to maintain an accurate and complete daily written Seizure Calendar for the entire duration of the Treatment and Taper Phases 7. Has given written informed consent prior to the performance of any study assessments. 8. A female subject is eligible to enter and participate in the study if she is not pregnant or lactating or planning to become pregnant during the study and is of: a. Non-childbearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is pre-menarchal or post-menopausal). • Pre-menopausal females with a documented (medical report verification) hysterectomy with or without oophorectomy or bi-lateral oophorectomy when reproductive status has been confirmed by hormone level assessment • Post-menopausal females defined as being amenorrhoeic for greater than one year with an appropriate clinical profile (e.g., age appropriate, history of vasomotor symptoms). However, if indicated, this should be confirmed by oestradiol and follicle stimulating hormone (FSH) levels consistent with menopause (according to local laboratory ranges). Women who have not been confirmed as post-menopausal should be advised to use contraception as outlined in Appendix 2 of Protocol. b. Child-bearing potential, has a negative serum pregnancy test at screening and randomization, and agrees to satisfy one of the requirements in as listed in Appendix 2 of protocol. 9. Liver function tests: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%). 10. Has a normal creatinine clearance (age corrected) as calculated with the Cockcroft-Gault formula. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults
Exclusion criteria
Exclusion criteria: Subjects meeting any of the following criteria must not be enrolled in the study: 1. Has generalized epilepsy (e.g., Lennox-Gastaut, Juvenile Myoclonic epilepsy, Absence, etc). 2. Has had status epilepticus (other than simple partial status epilepticus) within the 12 months prior to Screening or during the Baseline Phase. 3. Has a history of innumerable seizures within the 12 months prior to Screening where the individual seizures cannot be counted. 4. Has a history of pseudo seizures, non-epilepsy events or any other type of psychogenic seizures that could be confused with seizures. 5. Acute Urinary Retention (treated or untreated) within 6 months of screening or an episode of Acute Urinary Retention (treated) within the last two years with symptoms within the last 6 months. 6. Screening AUA SI Score >7 (>11 for subject over 55 years old). 7. Flowmetry Peak Flow 125mL or >40% functional residual volume at Screening. 9. Prior history of administration of BOTOX™ within genitourinary system. 10. Prior history or any type of medical or surgical therapy for urinary incontinence. 11. Prior history of treated or untreated, bladder, prostate, uterine or cervical cancer. 12. Use of sildenafil, tadalafil, vardenafil or other PDE-5 inhibitors within 2 weeks of study start. 13. Use of a-adrenoreceptor antagonists within 2 weeks of study start. 14. Has had previous exposure to ezogabine/retigabine. 15. Is currently or has been abusing substance(s) or any medications in the 12 months prior to Screening. 16. Has taken an investigational drug, or used an investigational device, within the previous 4 weeks prior to Screening or plans to take another investigational drug anytime during the study. 17. Is currently following or planning to follow the ketogenic diet. 18. Has been treated with felbamate or vigabatrin within the past 6 months prior to Screening; if a subject has been previously treated with vigabatrin, a visual perimetry test prior to screening (or within the past 6 months) must show normal visual fields or no worsening of recognized visual field abnormalities as compared with prior to vigabatrin treatment. 19. Use of CNS-active medication (other than concomitant AED therapy), unless subjects had been stabilized on such medication for more than 4 weeks prior to Screening. 20. Use of herbal treatments with CNS activity within 4 weeks prior to Screening. 21. Current use of any prohibited concomitant medication as indicated in Section 5.7.2 of the protocol. 22. Is planning surgery to control seizures during the study. 23. Is suffering from acute or progressive neurological disease, severe psychiatric disease, or severe mental abnormalities that, in the investigator’s judgment, are likely to interfere with the objectives of the study. 24. Has any medical condition that, in the investigator’s judgment, is considered to be clinically significant and could potentially affect subject safety or study outcome, including but not limited to: clinically significant cardiac, renal, hepatic condition, or a condition that affects the absorption, distribution, metabolism or excretion of drugs. 25. Has an average QTc =450 msec or =480 msec for subjects with Bundle Branch Block at the time of Screening. Note: If the initial electrocardiogram (ECG) at Screening indicates a corrected QT (QTc) interval outside these limits, tw
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To evaluate the effect of ezogabine/retigabine added to existing antiepileptic drug(s) on voiding function of adult subjects with drug-resistant partial onset seizures POS on 1-3 AEDs. This will be achieved with flowmetry measurement (Maximum Flow Rate Qmax) and assessment of Post-void residual (PVR) by bladder ultrasound.;Secondary Objective: To evaluate the effects of ezogabine/retigabine added to existing antiepileptic drug(s) on American Urological Association Symptom Index (AUA SI) in epilepsy subjects with drug-resistant POS on 1-3 AEDs. To explore the effects of ezogabine/retigabine added to existing antiepileptic drug(s) on secondary measurements of flowmetry [Voided Volume (VV), Time to Maximum Flow, Flow Time, Average Flow Rate (Qmean)], and a composite endpoint based on absolute decrease in Qmax, percent increase in residual volume and presence of hesitation or lower urinary tract (LUT) symptoms. To further evaluate the effects of ezogabine/retigabine on voiding function, subjects who meet pre-determined criteria for voiding dysfunction will undergo multichannel cystometry in order to characterise bladder hypocontractility, bladder outlet obstruction or a combination of events which clinically is manifest with difficulty emptying the bladder or acute urinary retention. ;Primary end point(s): Uroflowmetry: change from baseline in Maximum Flow Rate (Qmax) at Visit 5.;Timepoint(s) of evaluation of this end point: Visit 5. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): • Uroflowmetry: change from baseline in Maximum Flow Rate (Qmax) at Visits 3, 4 and 6. percent change from baseline in Qmax at Visits 3, 4, 5 and 6. • Change from baseline in %RUV at Visits 3, 4, 5 and 6. • Uroflowmetry: change from baseline in Voided Volume (VV), Time to Maximum Flow, Flow Time baseline, and Average Flow Rate (Qmean) at each post-baseline visit. • Frequency of micturition and Volume voided as recorded on the Voiding Diary for 2 days prior to each post-baseline visit. • Change from baseline in AUA SI at each post-baseline visit. • Cystometry data will be summarised individually for each subject.;Timepoint(s) of evaluation of this end point: Visits 3, 4, 5 and 6. | — |
Countries
France, Poland, Spain, United States
Contacts
Public ContactClinical Trials Helpdesk
GlaxoSmithKline Research and Development Limited
Outcome results
None listed